呋塞米/地高辛(Furosemide/Digoxin) - 药物靶点：NKCC2_在研适应症：光化性角化病，尖锐湿疣，外阴肿瘤_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Digoxin/furosemide、ICVT

靶点

NKCC2

作用机制

NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

Cutanea Life Sciences, Inc.Henderson Morley Plc

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C41H64O14

InChIKeyLTMHDMANZUZIPE-PUGKRICDSA-N

CAS号20830-75-5

查看全部结构式(2)

关联

5

项与呋塞米/地高辛相关的临床试验

NCT05599971 / Not yet recruitingN/AIIT

The Efficacy of Intralesional Injection of Combined Digoxin and Furosemide Versus 5-Flurouracil in the Treatment of Plantar Warts

The aim of the current work is to evaluate the efficacy and safety of intralesional combined Digoxin and furosemide versus intralesional 5-flurouracil in the treatment of plantar warts.

开始日期2023-02-22

申办/合作机构

Zagazig University

NCT03684772 / Unknown status临床2期

A Phase 2, Randomized, Double Blind, Vehicle Controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics and Safety of Topical Ionic Contra-Viral Therapy (ICVT) Comprised of Digoxin and Furosemide in Actinic Keratosis

To explore the pharmacodynamics and evaluate safety, tolerability and clinical efficacy of ICVT comprised of digoxin and furosemide (dual agent), digoxin (single agent), furosemide (single agent) in patients with AK.

开始日期2018-10-22

申办/合作机构

Maruho Co., Ltd.

NCT03334240 / Terminated临床2期

A Phase 2, Randomized, Vehicle-controlled, Double-blind Study to Explore the Efficacy, Pharmacodynamics and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients

This study is intended to explore and evaluate the pharmacodynamics and clinical efficacy of the ionic contra-viral therapy CLS003 in immunocompromised and immunocompetent patients with benign and premalignant HPV-induced genital lesions

开始日期2017-10-05

申办/合作机构

Maruho Co., Ltd.

100 项与呋塞米/地高辛相关的临床结果

登录后查看更多信息

100 项与呋塞米/地高辛相关的转化医学

登录后查看更多信息

100 项与呋塞米/地高辛相关的专利（医药）

登录后查看更多信息

4

项与呋塞米/地高辛相关的文献（医药）

2019-07-03·Expert Opinion on Investigational Drugs2区 · 医学

Investigational drugs currently in phase II clinical trials for actinic keratosis

2区 · 医学

Review

作者: Mazzeo, Mauro ; Lozzi, Flavia ; Bianchi, Luca ; Garofalo, Virginia ; Mazzilli, Sara ; Diluvio, Laura ; Terrinoni, Alessandro ; Palumbo, Vincenzo ; Lanna, Caterina ; Campione, Elena

INTRODUCTIONActinic keratoses (AKs) are limited areas of irregular epidermal growth on a background of excessive solar exposure. The entire sun-damaged skin is considered a field of cancerization with multiple visible and subclinical lesions. AK management requires field-directed therapies to block lesion relapse and prevent squamous cell carcinoma (SCC).AREAS COVEREDIn this review, we focused on phase II clinical trials for AKs, involving well-known agents and newer molecules such as proapoptotic drugs (VDA-1102, SR-T100, oleogel-S10, ICVT, eflornithine), immunomodulants (isotretinoin, tretinoin) and chemopreventive agents (nicotinamide, perillyl alcohol, liposomal T4N5). We used the website 'ClinicalTrials.Gov' as main reference. We selected and discussed completed and ongoing trials and analysed chemical structure and mechanism of action of the investigated molecules.EXPERT OPINIONAK therapy should be tailored on the patient's profile considering first of all the age and site of the AKs, which are relevant parameters for local immune response. The new molecules could be combined to obtain a synergic effect blocking the different steps of skin tumorigenesis. Phase II trials highlight a new therapeutic opportunity to block selectively cell proliferation regulators and work both on the field of cancerization and on the AKs currently present.

2019-05-01·British Journal of Dermatology1区 · 医学

A randomized controlled proof‐of‐concept trial of digoxin and furosemide in adults with cutaneous warts

1区 · 医学

Article

作者: Kouwenhoven, S. ; Burggraaf, J. ; Rijsbergen, M. ; Feiss, G. ; Hogendoorn, G. ; de Koning, M. ; Lemoine, C. ; Rissmann, R. ; Klaassen, E.S. ; Niemeyer‐van der Kolk, T. ; Beck, S. ; Bouwes Bavinck, J.N.

BACKGROUNDTopical ionic contraviral therapy (ICVT) with digoxin and furosemide inhibits the potassium influx on which DNA viruses rely for replication. Therefore, ICVT was hypothesized to be a potential novel treatment for cutaneous warts.OBJECTIVESTo assess the clinical efficacy, safety and tolerability of ICVT in adults with cutaneous warts. The secondary objective was to gain insight into the underlying working mechanism of ICVT.METHODSTreatment with ICVT was assessed for efficacy, safety and tolerability in a single- centre, randomized, double-blind, placebo-controlled phase IIA trial. Eighty adult patients with at least two cutaneous warts (plantar or common) were randomized to one of four treatments: digoxin + furosemide (0·125%), digoxin (0·125%), furosemide (0·125%) or placebo. The gel was administered once daily for 42 consecutive days. Predefined statistical analysis was performed with a mixed-model ancova. The trial was registered at ClinicalTrials.gov with number NCT02333643.RESULTSWart size and human papillomavirus (HPV) load reduction was achieved in all active treatment groups. A statistically significant reduction in wart diameter of all treated warts was shown in the digoxin + furosemide treatment group vs. placebo (-3·0 mm, 95% confidence interval -4·9 to -1·1, P = 0·002). There was a statistically significant reduction in the HPV load of all treated warts in the digoxin + furosemide group vs. placebo (-94%, 95% confidence interval -100 to -19, P = 0·03). With wart size reduction, histologically and immunohistochemically defined viral characteristics disappeared from partial and total responding warts.CONCLUSIONSThis study demonstrates the proof of concept for the efficacy of topical ICVT in adults with cutaneous warts.

2017-12-01·Journal of the European Academy of Dermatology and Venereology

Topical ionic contra‐viral therapy comprised of digoxin and furosemide as a potential novel treatment approach for common warts

Article

作者: de Koning, M.N.C. ; Genders, R.E. ; Burggraaf, J. ; Klaassen, E.S. ; Rijneveld, R. ; Bouwes Bavinck, J. N. ; Dillingh, M.R. ; van der Kolk, T. ; Feiss, G. ; Kouwenhoven, S.T.P. ; Rissmann, R.

AbstractBackgroundDNA viruses such as HPV rely on K+ influx for replication. Both digoxin and furosemide inhibit the K+ influx by interacting with cell membrane ion co‐transporters (Na+/K+‐ATPase and Na+‐K+‐2Cl− co‐transporter‐1, respectively). We therefore hypothesized that these two compounds in a topical formulation may be valuable in the treatment of HPV‐induced warts. This new approach is called Ionic Contra‐Viral Therapy (ICVT).ObjectiveTo evaluate systemic exposure, safety and tolerability of ICVT with a combination of furosemide and digoxin after repeated topical application in subjects with common warts. Furthermore, we aimed to evaluate pharmacodynamics effects of ICVT.MethodsTwelve healthy subjects with at least four common warts on their hands were included in the study and treated with a fixed dose of 980 mg topical gel containing 0.125% (w/w) digoxin and 0.125% (w/w) furosemide for 7 consecutive days on their lower back to assess safety and systemic exposure. Two warts were treated with 10 mg each and two served as negative controls to obtain preliminary evidence of treatment effect.ResultsICVT was well tolerated topically, and there was no evidence of systemic exposure of digoxin or furosemide. There were no clinical relevant safety findings and no serious adverse events (SAEs). A rapid and statistically significant reduction in diameter, height and volume of the warts was already observed at day 14.ConclusionICVT was found to be safe for administration to humans and 7 days of active treatment showed a statistical significant wart reduction compared to untreated control lesions, clearly indicating pharmacological activity.

100 项与呋塞米/地高辛相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
光化性角化病	临床2期	荷兰	Cutanea Life Sciences, Inc.	-
光化性角化病	临床2期	-	Cutanea AS	-
尖锐湿疣	临床2期	荷兰	Cutanea Life Sciences, Inc.	-
尖锐湿疣	临床2期	-	Cutanea AS	-
单纯疱疹	临床2期	美国	Cutanea Life Sciences, Inc.	-
乳头状瘤病毒感染	临床2期	英国	Henderson Morley Plc	-
感染性角结膜炎	临床2期	奥地利	-	-
感染性角结膜炎	临床2期	斯洛伐克	-	-
外阴上皮内瘤变	临床2期	荷兰	Cutanea Life Sciences, Inc.	-
外阴肿瘤	临床2期	-	Cutanea AS	-